We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBE SCIENTIFIC, LLC

BIO-RAD LABORATORIES

Provides full range of instrumentation, reagent kits, software and quality control systems to clinical laboratories. ... read more Featured Products: More products

Download Mobile App




Bio-Rad to Acquire Digital PCR Developer Stilla Technologies

By LabMedica International staff writers
Posted on 14 Feb 2025

Bio-Rad Laboratories (Hercules, CA, USA) has entered into a binding offer to purchase all equity interests in Stilla Technologies (Villejuif, France). More...

The acquisition remains subject to consultation with relevant employee representatives, regulatory approvals, and other customary closing conditions, and is expected to close by the end of the third quarter of 2025.

With operations in France and the U.S., Stilla develops and markets next-generation digital PCR instruments, consumables, and assays. The company’s Nio family of all-in-one digital PCR systems aids the development of a wide range of genetic tests and molecular assays across multiple applications including liquid biopsy for oncology diagnostics, cell and gene therapy, organ transplant testing, infectious diseases, and food and environmental testing.

"Stilla’s next-generation digital PCR solutions would make a compelling and complementary addition to Bio-Rad’s best-in-class digital PCR portfolio,” said Norman Schwartz, CEO of Bio-Rad Laboratories. “Once closed, the acquisition will support our strategy to further expand our business into applied research and clinical diagnostics where customers expect a higher degree of automation and throughput capabilities.”

“Together with our planned launch of Bio-Rad’s QX Continuum system, the Stilla platform would allow us to serve the full range of digital PCR applications and help us meet the evolving needs of customers in genomics research and applied science,” added Jim Barry, EVP and President of Bio-Rad’s Life Science Group.

“We are thrilled with the prospect of joining Bio-Rad, a leader in the field of digital PCR,” stated Rémi Dangla, CEO of Stilla Technologies. “With Stilla’s passion for product development and Bio-Rad’s extensive life science expertise, operational excellence, and global reach, together we can bring substantial value to the work of applied research and biopharma customers around the globe.”

Related Links:
Bio-Rad Laboratories
Stilla Technologies


Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Serological Pipet Controller
PIPETBOY GENIUS
New
PBC Assay
Primary Biliary Cholangitis Assays
New
Shaking Incubator
Corning LSE 71L
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: Schematic overview of the deep learning-based circulating exosome analysis for lung cancer detection (Photo courtesy of Chuan Xu, Cheng Jiang)

Liquid Biopsy Approach to Transform Diagnosis, Monitoring and Treatment of Lung Cancer

Lung cancer continues to be a major contributor to cancer-related deaths globally, with its biological complexity and diverse regulatory processes making diagnosis and treatment particularly difficult.... Read more

Pathology

view channel
Image: The Aiforia Breast Cancer Grading AI solution is CE-IVD marked (Photo courtesy of Aiforia Technologies)

Clinical AI Solution for Automatic Breast Cancer Grading Improves Diagnostic Accuracy

Labs that use traditional image analysis methods often suffer from bottlenecks and delays. By digitizing their pathology practices, labs can streamline their work, allowing them to take on larger caseloads... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.